<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902021000201201</article-id>
<article-id pub-id-type="doi">10.29193/rmu.37.2.1</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Rendimiento del antígeno carcinoembrionario como prueba diagnóstica del cancer colorrectal]]></article-title>
<article-title xml:lang="en"><![CDATA[Effectiveness of carcinoembryonic antigen to diagnose colorectal cancer]]></article-title>
<article-title xml:lang="pt"><![CDATA[Desempenho do antígeno carcinogênico embrionário como teste diagnóstico do câncer colorretal]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González González]]></surname>
<given-names><![CDATA[Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruso Martínez]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Cooperativa Médica de Florida  Servicio de Cirugía]]></institution>
<addr-line><![CDATA[Florida ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de la República Facultad de Medicina Hospital Maciel]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de la República Facultad de Medicina Hospital Maciel]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<volume>37</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902021000201201&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902021000201201&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902021000201201&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  el antígeno carcinoembrionario (CEA) es un marcador tumoral de seguimiento y no una prueba de tamizaje y diagnóstico en cáncer colorrectal (CCR). Sin embargo, en la práctica clínica habitual se continúa solicitando con fines de diagnóstico inicial.  Objetivo:  evaluar el rendimiento del CEA para el diagnóstico de CCR en el Hospital Maciel y en la Cooperativa Médica de Florida, en el período 2000-2019.  Material y método:  se trata de un estudio prospectivo de evaluación del CEA como prueba diagnóstica del CCR. Los criterios de inclusión fueron: 1) videocolonoscopía total en los usuarios sin CCR y videocolonoscopía total o parcial para aquellos con CCR y la confirmación histológica de adenocarcinoma; 2) contar con determinación de CEA dentro de los 30 días previos o posteriores a la videocolonoscopía, y 3) para la estadificación, el informe anatomopatológico de la pieza quirúrgica y la confirmación histológica de metástasis a distancia. El número de casos incluidos se determinó por un mínimo de diez casos en cada celda de la tabla de contingencia.  Resultados:  se analizaron 211 casos. El análisis general determinó una sensibilidad de 33,6%, especificidad 70,4%, valor predictivo positivo (VPP) 69,1%, valor predictivo negativo (VPN) 35%, exactitud 45,9%. Para el estadio II, sensibilidad 18,8%, especificidad 70,4%, VPP 30%, VPN 56,2%, exactitud 49,5%. Estadio III: sensibilidad 31,6%, especificidad 70,4%, VPP 36,4%, VPN 65,8%, exactitud 56,8%. Estadio IV: sensibilidad 65%, especificidad 70,4%, VPP 55,3%, VPN 78,1%, exactitud 68,4%.  Conclusiones:  el CEA como prueba de confirmación diagnóstica del CCR muestra un bajo rendimiento, siendo aun menor en estadios precoces de la enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary:  Introduction:  carcinoembryonic antigen (CEA) is a tumor marker used for follow up rather than a screening and diagnostic test for colorectal cancer (CCR). However, it continues to be requested in the regular clinical practice for initial diagnosis.  Objective:  to evaluate the effectiveness of CEA to diagnose colorectal cancer at Maciel Hospital and Cooperativa Medica de Florida Hospital from 2000 to 2019.  Method:  prospective study to evaluate CEA as a diagnostic test for colorectal cancer. The following inclusion criteria were used: 1) total videocolonoscopy in all users without CLC and total or partial videocolonoscopy for those with CRC and histologic confirmation of adenocarcinoma; 2) CEA determination within 30 days before or after videocolonoscopy and 3) for the purpose of staging, pathology report of the surgical piece and histological confirmation of distant metastases. The number of cases included was defined by a 10-case minimum in each cell of the contingency table.  Results:  211 cases were analysed. The general analysis revealed 33.6% sensitivity, 70.4% specificity, VPP 69.1%, VPN 35%, accuracy 45.9%. In the case of staging II, sensitivity was 18.8%, specificity 70.4%, VPP 30%, VPN 56.2%, accuracy 49.5%. In the case of staging III, sensitivity 31.6%, specificity 70.4%, VPP 36.4%, VPN 65.8%, accuracy 56.8%. In the case of staging IV, sensitivity 65%, specificity 70.4%, VPP 55.3%, VPN 78.1%, accuracy 68.4%.  Conclusions:  CEA evidences low effectiveness to diagnose colorectal cancer, and it is still less effective in early stages of the disease.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  o antígeno carcinogênico embrionário (CEA) é um marcador tumoral de acompanhamento e não um teste de rastreamento e diagnóstico em câncer colorretal (CRC). No entanto, na prática clínica de rotina, continua a ser solicitado nos diagnósticos iniciais.  Objetivo:  avaliar o desempenho do CEA no diagnóstico de câncer colorretal nos Hospitais Maciel de Montevidéu e da Cooperativa Médica de Florida, no período 2000-2019.  Material e método:  este é um estudo prospectivo avaliando o CEA como teste diagnóstico para câncer colorretal. Os critérios de inclusão foram: 1) videocolonoscopia total em usuários sem CCR e videocolonoscopia total ou parcial naqueles com CCR e confirmação histológica de adenocarcinoma; 2) determinação do CEA 30 dias antes ou após a videocolonoscopia e 3) estadiamento, laudo anatomopatológico da peça cirúrgica e confirmação histológica de metástases à distância. O número de casos incluídos foi determinado por um mínimo de 10 casos em cada célula da tabela de contingência.  Resultados:  foram analisados 211 casos. A análise geral determinou uma sensibilidade de 33,6%, especificidade 70,4%, VPP 69,1%, VPN 35%, precisão 45,9%. Para o estágio II, sensibilidade 18,8%, especificidade 70,4%, PPV 30%, NPV 56,2%, precisão 49,5%. Estágio III, sensibilidade 31,6%, especificidade 70,4%, PPV 36,4%, NPV 65,8%, precisão 56,8%. Estágio IV, sensibilidade 65%, especificidade 70,4%, PPV 55,3%, NPV 78,1%, precisão 68,4%.  Conclusões:  o CEA como teste de confirmação diagnóstica do câncer colorretal apresenta baixo desempenho, sendo ainda menor nos estágios iniciais da doença.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Antígeno carcinoembrionario]]></kwd>
<kwd lng="es"><![CDATA[Neoplasias colorrectales]]></kwd>
<kwd lng="es"><![CDATA[Diagnóstico]]></kwd>
<kwd lng="es"><![CDATA[Tamizaje]]></kwd>
<kwd lng="en"><![CDATA[Carcinoembryonic antigen]]></kwd>
<kwd lng="en"><![CDATA[Colorectal neoplasms]]></kwd>
<kwd lng="en"><![CDATA[Diagnosis]]></kwd>
<kwd lng="en"><![CDATA[Screening]]></kwd>
<kwd lng="pt"><![CDATA[Antígeno carcinoembrionário]]></kwd>
<kwd lng="pt"><![CDATA[Neoplasias colorretais]]></kwd>
<kwd lng="pt"><![CDATA[Diagnóstico]]></kwd>
<kwd lng="pt"><![CDATA[Rastreamento]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Comisión Honoraria de Lucha Contra el Cáncer. Registro Nacional de Cáncer</collab>
<source><![CDATA[Situación epidemiológica del Uruguay en relación al cáncer. Incidencia del cáncer en el quinquenio 2011-2015. Tendencia de la mortalidad por cáncer hasta 2017]]></source>
<year>2019</year>
<page-range>61</page-range><publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[CHLC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública. Dirección General de la Salud. Programa Nacional de Prevención del Cáncer</collab>
<article-title xml:lang=""><![CDATA[Antígeno carcinoembrionario]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muse]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Masetti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sosa Basaistegui]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Suarez Hinojosa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Terradas]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de oncología para el primer nivel de atención]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[Del Este Sol]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>ASCO</collab>
<article-title xml:lang=""><![CDATA[ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Locker]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jessup]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Kemeny]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Macdonald]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2006</year>
<volume>24</volume>
<numero>33</numero>
<issue>33</issue>
<page-range>5313-27</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sturgeon]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Dubby]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stenman]]></surname>
<given-names><![CDATA[UH]]></given-names>
</name>
<name>
<surname><![CDATA[Lilja]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Brunner]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use os tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>2008</year>
<volume>54</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>e11-79</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ruso Martínez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Criterio de solicitud del antígeno carcinoembrionario (CEA) en el Hospital de Florida (julio 2012-julio 2013)]]></article-title>
<source><![CDATA[Rev Méd Urug]]></source>
<year>2016</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>98-103</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Pedraza]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Echeverry Raad]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspectos sobre diseño y tamaño de muestra en estudios de pruebas diagnósticas]]></article-title>
<source><![CDATA[Rev Fac Med UN Col]]></source>
<year>2001</year>
<volume>49</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>175-80</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Sohn]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum CEA and CA 19-9 levels are associated with de presence and severity of colorectal neoplasia]]></article-title>
<source><![CDATA[Yonsei Med J]]></source>
<year>2017</year>
<volume>58</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>918-24</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma]]></article-title>
<source><![CDATA[Int J Clin Exp Pathol]]></source>
<year>2015</year>
<volume>8</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>9404-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nikolouzakis]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
<name>
<surname><![CDATA[Vassilopoulou]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fragkiadaki]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sapsakos]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Papadakis]]></surname>
<given-names><![CDATA[GZ]]></given-names>
</name>
<name>
<surname><![CDATA[Spandidos]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving diagnosis, prognosis and prediction by using biomarkers in CRC patientes (Review)]]></article-title>
<source><![CDATA[Oncol Rep]]></source>
<year>2018</year>
<volume>39</volume>
<page-range>2455-72</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gouvas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nicholls]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ziprin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Xynos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tekkis]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic precision of carcinoembryionic antigen in the detection of recurrence of colorectal cancer]]></article-title>
<source><![CDATA[Surg Oncol]]></source>
<year>2009</year>
<volume>18</volume>
<page-range>15-24</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duffy]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lamerz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Haglund]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kalousová]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Holubec]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guideline update]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2014</year>
<volume>134</volume>
<page-range>2513-22</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lech]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Slotwinsky]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Slodkowki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Krasnodebski]]></surname>
<given-names><![CDATA[IW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Colorectal cancer tumor markrers and biomarers: recent therapeutic advences]]></article-title>
<source><![CDATA[World J Surg]]></source>
<year>2016</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1745-55</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carbajal Garcés]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Morales Clavijo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sensibilidad y especificidad de los marcadores tumorales]]></article-title>
<source><![CDATA[Rev Méd (Cochabamba)]]></source>
<year>2010</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>86-97</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hornig]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Molt]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mariángel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Avendaño]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antígeno carcinoembrionario preparatorio y riesgo de metástasis en el cáncer colorectal]]></article-title>
<source><![CDATA[Cuad Cir]]></source>
<year>2005</year>
<volume>19</volume>
<page-range>22-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duffy]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoembryonic antigen as a marker for colorectal cáncer: is it clinically useful?]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>2001</year>
<volume>47</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>624-30</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorbye]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2003</year>
<volume>21</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>4466-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rademaker]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Platt]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving colon cancer screening in community clinics]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2013</year>
<volume>119</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>3879-86</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Téllez-Avila]]></surname>
<given-names><![CDATA[FI]]></given-names>
</name>
<name>
<surname><![CDATA[García-Osogobio]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El antígeno carcinoembrionario: a propósito de un viejo conocido]]></article-title>
<source><![CDATA[Rev Invest Clin]]></source>
<year>2005</year>
<volume>57</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>814-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Terdiman]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Colorectal cancer screening: scientific review]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2003</year>
<volume>289</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1288-96</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leddin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Champion]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cockeram]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Flook]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: guidelines on colon cancer screening]]></article-title>
<collab>Gould M et al</collab>
<source><![CDATA[Can J Gastroenterol]]></source>
<year>2004</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>93-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iade]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Tchekmedyian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bianchi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[San Martín]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Raggio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones de la Sociedad de Gastroenterología del Uruguay para la detección precoz y el seguimiento del cáncer colorrectal]]></article-title>
<source><![CDATA[Rev Méd Uruguay]]></source>
<year>2003</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>172-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bast Jr]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Ravdin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Bates]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fritsche Jr]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jessup]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2000 update of recommendations for the use of tumor markers in breast and colorectal cáncer: clinical practice guidelines of the American Society of Clinical Oncology]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2001</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1865-78</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<collab>Ruiz de Adana Pérez R</collab>
<article-title xml:lang=""><![CDATA[Eficacia de una prueba diagnóstica: parámetros utilizados en el estudio de un test]]></article-title>
<source><![CDATA[JANO]]></source>
<year>2009</year>
<numero>1736</numero>
<issue>1736</issue>
<page-range>30</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fletcher]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoembryonic antigen]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1986</year>
<volume>104</volume>
<page-range>66-73</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Van Dalen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sibley]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Kasper]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Durham]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[El Shami]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multicentre tumour marker reference range study]]></article-title>
<source><![CDATA[Anticancer Res]]></source>
<year>1999</year>
<volume>19</volume>
<numero>4A</numero>
<issue>4A</issue>
<page-range>2749-52</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
